



SUPPLEMENTARY FIG. S2. Immunostaining and quantification of lumican and fibulin 5 expression of infarcts treated with miR-239B and miR-29B. No significant difference in GVI of lumican or fibulin 5 was detected between the treatment of miR-239B (control) and miR-29B. Scale bar: 50 μ m. GVI, gray value intensities.